Display options
Cite
Thivolet M, Kornfeld A, Toumi M. Health Technology Assessments In Oncology: Crizotinib Case Study. Value Health. 2014;17(7):A661doi: 10.1016/j.jval.2014.08.2424.
Thivolet, M., Kornfeld, A., & Toumi, M. (2014). Health Technology Assessments In Oncology: Crizotinib Case Study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A661. https://doi.org/10.1016/j.jval.2014.08.2424
Thivolet, M, et al. "Health Technology Assessments In Oncology: Crizotinib Case Study." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A661. doi: https://doi.org/10.1016/j.jval.2014.08.2424
Thivolet M, Kornfeld A, Toumi M. Health Technology Assessments In Oncology: Crizotinib Case Study. Value Health. 2014 Nov;17(7):A661. doi: 10.1016/j.jval.2014.08.2424. Epub 2014 Oct 26. PMID: 27202404.
Copy Download .nbib Format: NLM
Share it on

Value Health. 2014 Nov;17(7):A661. doi: 10.1016/j.jval.2014.08.2424. Epub 2014 Oct 26.

Health Technology Assessments In Oncology: Crizotinib Case Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

M Thivolet, A Kornfeld, M Toumi

Affiliations

  1. Creativ-Ceutical, Paris, France.
  2. University Aix-Marseille, Marseille, France.

PMID: 27202404 DOI: 10.1016/j.jval.2014.08.2424

[No abstract available.]

Publication Types